CA2972128A1 - Fgf21 derivatives and uses thereof - Google Patents

Fgf21 derivatives and uses thereof Download PDF

Info

Publication number
CA2972128A1
CA2972128A1 CA2972128A CA2972128A CA2972128A1 CA 2972128 A1 CA2972128 A1 CA 2972128A1 CA 2972128 A CA2972128 A CA 2972128A CA 2972128 A CA2972128 A CA 2972128A CA 2972128 A1 CA2972128 A1 CA 2972128A1
Authority
CA
Canada
Prior art keywords
ethoxy
amino
fgf21
chem
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2972128A
Other languages
English (en)
French (fr)
Other versions
CA2972128C (en
Inventor
Birgit Wieczorek
Tina Moller Tagmose
Kristian Sass-Orum
Birgitte Andersen
Jorgen Olsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CA2972128A1 publication Critical patent/CA2972128A1/en
Application granted granted Critical
Publication of CA2972128C publication Critical patent/CA2972128C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2972128A 2014-12-23 2015-12-22 Fgf21 derivatives and uses thereof Active CA2972128C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199935 2014-12-23
EP14199935.9 2014-12-23
PCT/EP2015/080969 WO2016102562A1 (en) 2014-12-23 2015-12-22 Fgf21 derivatives and uses thereof

Publications (2)

Publication Number Publication Date
CA2972128A1 true CA2972128A1 (en) 2016-06-30
CA2972128C CA2972128C (en) 2025-09-09

Family

ID=

Also Published As

Publication number Publication date
AU2015371056B2 (en) 2020-06-25
US20180140673A1 (en) 2018-05-24
MY181181A (en) 2020-12-21
HRP20191292T1 (hr) 2019-10-18
RS59154B1 (sr) 2019-10-31
US20170182124A1 (en) 2017-06-29
TWI681966B (zh) 2020-01-11
RU2729011C2 (ru) 2020-08-03
KR102427527B1 (ko) 2022-08-01
HUE044783T2 (hu) 2019-11-28
PT3236991T (pt) 2019-09-06
MX2017007458A (es) 2017-08-10
HK1246156B (en) 2020-03-27
RU2017125050A (ru) 2019-01-25
KR20170095256A (ko) 2017-08-22
EP3236991A1 (en) 2017-11-01
TW201632545A (zh) 2016-09-16
MX377044B (es) 2025-03-07
DK3236991T3 (da) 2019-08-26
ZA201703768B (en) 2020-05-27
SA517381673B1 (ar) 2020-10-29
US9744213B2 (en) 2017-08-29
EP3236991B1 (en) 2019-06-19
WO2016102562A1 (en) 2016-06-30
PL3236991T3 (pl) 2019-12-31
JP2018505146A (ja) 2018-02-22
IL252438B (en) 2021-09-30
RU2017125050A3 (enExample) 2019-06-06
SI3236991T1 (sl) 2019-09-30
CN107108709A (zh) 2017-08-29
TW202012431A (zh) 2020-04-01
IL252438A0 (en) 2017-07-31
ES2742503T3 (es) 2020-02-14
AR103246A1 (es) 2017-04-26
BR112017011552A2 (pt) 2018-02-14
CN107108709B (zh) 2021-12-14
US10124039B2 (en) 2018-11-13
AU2015371056A1 (en) 2017-06-15
US9895417B2 (en) 2018-02-20
US20170354713A1 (en) 2017-12-14
TWI708781B (zh) 2020-11-01
JP6727210B2 (ja) 2020-07-22

Similar Documents

Publication Publication Date Title
AU2015371056B2 (en) FGF21 derivatives and uses thereof
HK1246156A1 (en) Fgf21 derivatives and uses thereof
ES2692495T3 (es) Derivados del FGF21 con aglutinante de albúmina A-B-C-D-E- y sus usos
KR101813595B1 (ko) 장기적 생체 내 효능을 갖는 성장 호르몬
ES2831848T3 (es) Análogo de insulina humana A22K, desB27, B29R, desB30, acilado en la posición épsilon de la lisina 22
BRPI0607248A2 (pt) conjugado de um polipeptìdeo e um oligossacarìdeo, composição farmacêutica, uso do conjugado, e, processo para a preparação de um conjugado
JP2013533227A (ja) Fgf21類似体および誘導体
US20130252884A1 (en) Fgf21 analogues and derivatives
ES2805326T3 (es) Coagonistas estables del receptor de GLP-1/glucagón basados en GLP-1
KR20080016674A (ko) 트랜스글루타미나제 매개 성장 호르몬 컨쥬게이션
KR20130036290A (ko) 추가 이황화 결합을 함유하는 인슐린 유도체
WO2017220706A1 (en) Pharmaceutical compositions of fgf21 derivatives and uses thereof
US20120035099A1 (en) Fgf21 analogues and derivatives
CA2972128C (en) Fgf21 derivatives and uses thereof
BR112017011552B1 (pt) Derivados de uma proteína do fgf21 e uso terapêutico e/ou profilático dos mesmos
TW202438102A (zh) 融合化合物及其用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201217

EEER Examination request

Effective date: 20201217

EEER Examination request

Effective date: 20201217

EEER Examination request

Effective date: 20201217

EEER Examination request

Effective date: 20201217

EEER Examination request

Effective date: 20201217

EEER Examination request

Effective date: 20201217